| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c5ddced4c203e56346f054e364b141ba |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70557
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-78
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-75
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-745 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-75
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-745
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-78 |
| filingDate |
1995-06-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
1997-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_17596fe390a87023acea81728471674a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ddfd7776022fd3e9b9516f4031f4a8fb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2ae2c37a62ccae0989a0439fbe1f6a2b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_29e447f57cd192a4b1a3c0d1085e7dfb |
| publicationDate |
1997-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-5648330-A |
| titleOfInvention |
Method and composition for treating vascular graft occlusion |
| abstract |
The invention provides RGD containing peptides which are cyclized and contain hydrophobic moieties adjacent the carboxy terminus of the RGD sequence. Such peptides have an high affinity for the receptor IIb/IIIa and low affinity for the fibronectin and vitronectin receptors. Such peptides can be administered in a suitable physiologically acceptable carrier to therapeutically treat thrombosis. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005033026-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9532863-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7358284-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6933326-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9649499-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10953044-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6087332-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008243198-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6100236-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011200738-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10022214-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9913705-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10722339-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10327884-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6013625-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005074426-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9119886-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9271821-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9549805-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9999637-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8653632-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009023004-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6395873-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9782496-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010310506-A1 |
| priorityDate |
1990-04-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |